Skip to main content
. 2019 Aug 12;9:11661. doi: 10.1038/s41598-019-48152-x

Figure 5.

Figure 5

Pharmacological targeting of SMARCA4 impairs proliferation of SMARCA2-deficient ESCC KYSE-30 cells. (A) Schematic representation of siRNA/sgRNA-resistant SMARCA4 variant with substituted BRD9 bromodomain (SMARCA4res-BDBRD9). KYSE-30 cells were stably transduced with SMARCA4res-BDBRD9 followed by knock-out of endogenous SMARCA4 and generation of a monoclonal cell line (KYSE-30-SMARCA4res-BDBRD9). (B) Capillary Western immunoassay for SMARCA4 in parental KYSE-30 and KYSE-30-SMARCA4res-BDBRD9 upon dBRD9 treatment for 4 h with the indicated doses. GAPDH expression was used to monitor equal loading. Quantification of SMARCA4 expression (lower panel) is represented as mean ± SD of four independent experiments. (C) Cell viability assay. Parental KYSE-30 cells and KYSE-30-SMARCA4res-BDBRD9 were treated as indicated with dBRD9 and cell viability was determined ten days post treatment. Data are represented as mean ± SD of four independent experiments.